Intervet/Schering-Plough Animal Health has launched Posatex (1% Orbifloxacin, 0.1% Mometasone Furoate Monohydrate and 0.1% Posaconazole, Otic Suspension), a new once-a-day treatment for otitis externa in dogs.

Posatex combines an antibacterial, an anti-inflammatory and an antifungal medication in one, seven-day treatment which the company describes as the 'next generation' treatment for severe otitis externa in dogs, designed to make compliance easier and bring fast relief to dogs suffering from this painful condition.

Allan Weingarten, Director, Pharmaceutical Research, and Posatex R&D Project Leader, said: "As every dog owner knows, this is a 'nightmare' disease. As experts in otic products, we feel a special responsibility to keep improving medications and continuing to make the course of treatment more effective, quicker and easier for both dogs and their caregivers. The novel triazole antifungal posaconazole, new to animal health, is the latest example of innovation in this product area."

Posatex Otic Suspension, available in 7.5, 15 and 30g plastic bottles, is indicated for the treatment of otitis externa associated with susceptible strains of yeast (Malassezia pachydermatis) and bacteria (coagulase positive staphylococci, Pseudomonas aeruginosa and Enterococcus faecalis).

According to the company, posaconazole, the newest element in the three-in-one combination, has been shown to be particularly effective against Malassezia pachydermatis and more potent than other veterinary antifungals. Mometasone furoate monohydrate is a potent and safe anti-inflammatory and Orbifloxacin is a broad-spectrum antibiotic with proven efficacy against bacteria.

PS: Whilst you're here, take a moment to see our latest job opportunities for vet nurses.